A mitochondria-targeting peptide that stabilises cardiolipin and restores age-related energy production decline.
Selectively concentrates (~1000×) in the inner mitochondrial membrane (IMM) via electrostatic interaction with cardiolipin — an anionic phospholipid essential for cristae structure. Stabilises cardiolipin/cytochrome c complexes, preserving electron transport chain (ETC) efficiency and reducing superoxide leak.
Elamipretide (MTP-131) has been in Phase 2/3 clinical trials for heart failure with preserved ejection fraction (HFpEF) and Barth syndrome. It is one of the most advanced mitochondria-targeted therapeutics in clinical development.
The Szeto-Schiller (SS) peptide family was developed by Hazel Szeto and Peter Schiller. SS-31 selectively accumulates in the IMM without requiring a membrane potential, distinguishing it from other mitochondria-targeting compounds.